CTCFL and ICF syndrome: Aberrant hypomethylation has been hypothesized to contribute to cancer progression by activating oncogenes such as H-RAS [81], BORIS/CTCFL [184], FGFR1 [97], c-MYC [185], or by retrotransposon activation [186, 187] or by increasing chromosome instability as in ICF syndrome [188].